Stay updated on Upadacitinib vs Methotrexate in RA Clinical Trial
Sign up to get notified when there's something new on the Upadacitinib vs Methotrexate in RA Clinical Trial page.

Latest updates to the Upadacitinib vs Methotrexate in RA Clinical Trial page
- ChecktodayChange DetectedA sitewide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check7 days agoChange DetectedThe revision identifier in the footer of the ClinicalTrials.gov error page changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check14 days agoChange DetectedThe ClinicalTrials.gov footer revision label was updated from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record with an inaccessible error screen. This indicates the page is currently blocked from viewer access.SummaryDifference19%

- Check56 days agoChange DetectedThe page shows new related topics like 'Rheumatoid arthritis' and 'MedlinePlus Genetics' and adds a 'Revision: v3.6.6' label. These updates appear to reflect navigation and versioning metadata rather than changes to the study data.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page adds a 2015 U.S. NIH Grant/Contract funding line and removes related-topic entries including Rheumatoid arthritis and MedlinePlus Genetics from the related topics section, altering funding disclosure and topic associations.SummaryDifference0.1%

Stay in the know with updates to Upadacitinib vs Methotrexate in RA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Upadacitinib vs Methotrexate in RA Clinical Trial page.